

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

LIPP et al.

Group Art Unit: TBA

Serial No.: TBA

Examiner: TBA

Filed: December 20, 2001

For: TRANSDERMAL SYSTEM THAT CONTAINS A NEW HIGHLY POTENT GESTAGEN

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

4. (Amended) Transdermal system according to claim 1, characterized by a content of 0.1 to 20% by weight, preferably 1 to 15% of (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione in the matrix.

5. (Amended) Transdermal system according to claim 1, wherein the matrix comprises at least one crystallization inhibitor.

7. (Amended) Transdermal system according to claim 1, characterized by an additional content of at least one of the following penetration intensifiers: